ID
16007
Description
Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00050141
Link
https://clinicaltrials.gov/show/NCT00050141
Keywords
Versions (2)
- 5/2/16 5/2/16 -
- 6/26/16 6/26/16 -
Uploaded on
June 26, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Breast Cancer NCT00050141
Eligibility Breast Cancer NCT00050141
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
prior hormone therapy
Data type
boolean
Alias
- UMLS CUI [1,1]
- C1514463
- UMLS CUI [1,2]
- C0279025
Description
prior chemotherapy regimen
Data type
boolean
Alias
- UMLS CUI [1]
- C1514457
Description
previous therapy with farnesyl transferase inhibitor
Data type
boolean
Alias
- UMLS CUI [1,1]
- C1514463
- UMLS CUI [1,2]
- C1517132
Description
mestastases
Data type
boolean
Alias
- UMLS CUI [1,1]
- C2826244
- UMLS CUI [1,2]
- C0027627
Description
concomitant anticancer treatment
Data type
boolean
Alias
- UMLS CUI [1]
- C0920425
Description
former malignancies
Data type
boolean
Alias
- UMLS CUI [1]
- C0006826
Description
symptomatic peripheral neuropathy
Data type
boolean
Alias
- UMLS CUI [1]
- C0031117
Similar models
Eligibility Breast Cancer NCT00050141
- StudyEvent: Eligibility
C0027627 (UMLS CUI [2,1])
C0205187 (UMLS CUI [2,2])
C0279025 (UMLS CUI [1,2])
C0279025 (UMLS CUI [1,2])
C1517132 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,2])